Publications by authors named "B M D B Basnayake"
Objective: High disease activity status (HDAS) in patients with systemic lupus erythematosus (SLE) is associated with adverse long-term outcomes. We examined the frequency of lupus low disease activity state (LLDAS) and remission (REM) attainment in HDAS patients and whether their attainment was associated with improved patient outcomes.
Methods: Demographic, clinical and outcomes data, collected prospectively from a multinational cohort between 2013 and 2020, were analysed.
The waste sector is a substantial source of GHG emissions worldwide. Open dumping and internal combustion (IC) waste collection vehicles are significant sources of GHG emissions in Vavuniya. This research aims to estimate GHG emissions and recommend strategies to reduce emissions from the solid waste management sector.
View Article and Find Full Text PDFObjectives: The lupus low disease activity state (LLDAS) allows for certain clinical and/or serological activity of SLE, provided overall disease activity does not exceed predefined cut-offs. This study aimed to evaluate the outcomes of patients who achieved LLDAS with clinical activity, serological activity only or neither clinical nor serological activity.
Methods: Patients with SLE enrolled in a prospective multinational cohort from March 2013 to December 2020 who were in LLDAS at least once were included.
Article Synopsis
- The study aimed to determine if achieving Lupus Low Disease Activity State (LLDAS) leads to better outcomes for patients with newly diagnosed systemic lupus erythematosus (SLE).
- Data was collected from a longitudinal SLE cohort in 13 countries, focusing on patients diagnosed within the last year, revealing that these patients had higher disease activity and use of glucocorticoids, but less organ damage initially compared to older patients in the study.
- Results showed that while fewer patients in the recent onset group were in LLDAS at the start, they were more likely to achieve it during follow-up and LLDAS attainment was linked to a lower risk of disease flare-ups.
Objective: Disease activity monitoring in SLE includes serial measurement of anti-double stranded-DNA (dsDNA) antibodies, but in patients who are persistently anti-dsDNA positive, the utility of repeated measurement is unclear. We investigated the usefulness of serial anti-dsDNA testing in predicting flare in SLE patients who are persistently anti-dsDNA positive.
Methods: Data were analysed from patients in a multinational longitudinal cohort with known anti-dsDNA results from 2013 to 2021.